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The brain uses lactate produced by glycolysis as an
energy source. How lactate originated from the blood
stream is used to fuel brain metabolism is not clear. The
current study measures brain metabolic fluxes and esti-
mates the amount of pyruvate that becomes labeled in
glial and neuronal compartments upon infusion of
[3-13C]lactate. For that, labeling incorporation into car-
bons of glutamate and glutamine was measured by 13C
magnetic resonance spectroscopy at 14.1 Tand analyzed
with a two-compartment model of brain metabolism to
estimate rates of mitochondrial oxidation, glial pyruvate
carboxylation, and the glutamate–glutamine cycle as well
as pyruvate fractional enrichments. Extracerebral lactate
at supraphysiological levels contributes at least two-fold
more to replenish the neuronal than the glial pyruvate
pools. The rates of mitochondrial oxidation in neurons
and glia, pyruvate carboxylase, and glutamate–glutamine
cycles were similar to those estimated by administration
of 13C-enriched glucose, the main fuel of brain energy
metabolism. These results are in agreement with primary
utilization of exogenous lactate in neurons rather than
astrocytes. VC 2014 Wiley Periodicals, Inc.
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Although brain function depends on an adequate
supply of oxygen and glucose, brain energy requirements
can be fulfilled by oxidation of alternative substrates, such
as lactate (Dienel, 2012a). Lactate acts as a buffer between
glycolysis and mitochondrial oxidative metabolism, func-
tions as a regulator of cellular redox state by conversion to
pyruvate, and is exchanged as a fuel between cells and tis-
sues, depending on relative glycolytic and oxidative rates
(Brooks, 2009). Although the brain exports lactate at rest,
a net flux of lactate into the brain occurs at elevated blood
lactate levels (Gallagher et al., 2009; Rasmussen et al.,
2010; van Hall, 2010). Exogenous lactate is not a necessary
brain fuel in vivo, so cellular utilization of lactate in the
brain has been a matter of debate (Dienel, 2012b; Hertz,
2012). Lactate is generated and oxidized by both neurons
and astrocytes, but the magnitude and direction of cell-to-
cell lactate shuttling coupled to its oxidation and/or
release from the brain remains to be firmly established.
Two decades ago, Pellerin and Magistretti (1994) pro-
posed an astrocyte–neuron lactate shuttle in which gluta-
mate released into the synaptic cleft during synaptic
activity is cotransported with Na1 into astrocytes, leading
to stimulation of the Na1/K1 ATPase that, in turn, results
in stimulation of the glycolytic flux and increased glucose
uptake from surrounding capillaries. The end product of
glycolysis, lactate, is then exported by astrocytes and taken
up by neurons, where it can be oxidized in mitochondria
for ATP synthesis (Pellerin and Magistretti, 1994).
Recently, evidence in vivo has confirmed the require-
ment of astrocyte-derived lactate to sustain brain func-
tions. In particular, lactate produced by astrocytes from
either glucose or glycogen stores is involved in memory
processes (Newman et al., 2011; Suzuki et al., 2011) and
can be used as fuel for axonal function (Wender et al.,
2000) and for myelin synthesis in oligodendroglia (Rin-
holm et al., 2011; Lee et al., 2012). Because the end-feet
of astrocytes ensheath blood vessels, it is plausible that
blood-borne lactate is redirected from astrocytes to neu-
rons and oligodendrocytes for further oxidation.
Lactate administration is neuroprotective against
brain damage upon limited glucose and/or oxygen avail-
ability (Schurr et al., 1997, 2001), traumatic brain injury
(Cureton et al., 2010), and glutamate excitotoxicity
(Schurr et al., 1999; Ros et al., 2001; Berthet et al.,
2009). Because lactate requires oxygen for its metabolism,
and excitotoxicity increases lactate while reducing glucose
levels, effects of exogenous lactate in sparing brain glucose
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and reducing the extension of lesions may be related to its
intracellular signaling roles rather than to its role as a fuel.
In particular, lactate acts as a transmitter of metabolic
information by modulating prostaglandin action and cere-
bral vasodilatation causing cerebral blood flow to increase,
regulates the NADH/NAD1 redox ratio by conversion
to pyruvate, and activates the G-protein-coupled receptor
GPR81 (also known as hydroxycarboxylic acid receptor 1) in
neurons, astrocytes, and capillaries, inhibiting cAMP pro-
duction (Gordon et al., 2008; Bergersen and Gjedde,
2012; Lauritzen et al., 2014). Thus, lactate physiologically
produced by astrocytes may also function as a signaling
molecule.
Magnetic resonance spectroscopy (MRS) studies
have revealed similar peak patterns in 13C spectra after
infusion of 13C-enriched glucose and lactate, contrasting
with spectra obtained after infusing 13C-acetate that is
specifically oxidized in glial cells (Boumezbeur et al.,
2010). Metabolic studies in vivo using 13C MRS allow
the noninvasive quantification of fluxes through bio-
chemical pathways of oxidative metabolism in both neu-
rons and astrocytes (Lanz et al., 2013). Mathematical
modeling of 13C MRS data can be employed to estimate
further the relative contribution of 13C-enriched sub-
strates to mitochondrial oxidation within the neuronal
and astrocytic compartments (Jeffrey et al., 2013). There-
fore, the current study tests the hypothesis that exoge-
nously provided [3-13C]lactate is preferentially oxidized
in neurons rather than glial cells, leading to differential
fractional enrichment (FE) of the pyruvate pools, by using
13C MRS in vivo in the rat brain.
MATERIALS AND METHODS
Chemicals
Sodium [3-13C]lactate (45–55% w/w), 2HCl (20% w/w),
NaO2H (40% w/w) and 2H2O were purchased from Sigma-
Aldrich (Basel, Switzerland); isoflurane was purchased from
Nicholas Piramal India (London, United Kingdom); and a-
chloralose was purchased from Acros Organics (Geel, Belgium).
All other chemicals were of the purest grade available from
either Sigma-Aldrich or Merck (Darmstadt, Germany).
Animals
All experimental procedures involving animals were
approved by the local ethics committee (EXPANIM-SCAV,
Switzerland). Male Sprague-Dawley rats (2566 8 g, n5 8; pur-
chased from Charles River Laboratories) were briefly anesthe-
tized with 4% isoflurane in air and then were intubated and
mechanically ventilated with a mixture of 30% O2 in air by
using a pressure-driven ventilator (MRI-1; CWE, Ardmore,
PA). Witgh animals under 2% isoflurane anesthesia, catheters
were placed into a femoral artery and a femoral vein as previ-
ously described (Duarte et al., 2009). The artery was used for
blood sampling and for continuous monitoring of blood pres-
sure and heart rate with the SA Instruments (Stony Brook, NY)
animal monitoring system. The vein was used as an administra-
tion route for phosphate-buffered saline (PBS) solutions (in
mM: 2.7 KCl, 8.1 Na2HPO4, 1.5 KH2PO4, 137 NaCl) con-
taining a-chloralose (5 mg/ml, pH 7), [3-13C]lactate (0.9 M,
pH 5), or glucose (1.1 M, pH 7).
After surgery, anesthesia was achieved by administration
of 80 mg/kg a-chloralose, followed by continuous infusion at
28 mg/kg/hr. Arterial pH and pressures of O2 and CO2 were
measured with a blood gas analyzer (AVL Compact 3; Dia-
mond Diagnostics, Holliston, MA) and were adjusted by regu-
lating the respiratory rate and volume. Body temperature was
maintained at 37C.
The experimental procedure for infusion of [3-13C]lactate
was first established in three rats. Glucose was continuously
infused at 0.15 mmol/kg/min to avoid production of 13C-
enriched glucose from [3-13C]lactate in peripheral tissues. Then
rats received an exponential bolus of 0.5 mmol/kg of
[3-13C]lactate for 5 min and then a continuous infusion at 0.07
mmol/kg/min. This rate was then adjusted based on measured
plasma lactate levels. A sustained plasma lactate concentration
and FE were achieved by following this protocol, as confirmed
in collected plasma samples.
Plasma glucose and lactate concentrations were quantified
with the glucose and lactate oxidase methods, respectively, by
using GM7 Micro-Stat analyzers (Analox Instruments, London,
United Kingdom). FE of substrates in plasma samples was meas-
ured by MRS in vitro (Duarte et al., 2007).
MRS
All MRS experiments in vivo were carried out in a
DirectDrive spectrometer (Agilent Technologies, Palo Alto,
CA) interfaced with a 26-cm horizontal-bore 14.1-T magnet
(Magnex Scientific, Abingdon, United Kingdom) with a
home-built coil consisting of a 1H quadrature surface coil and a
13C linearly polarized surface coil, as detailed previously
(Duarte et al., 2011). Briefly, the static magnetic field in the
brain (volume of interest 320 ml) was homogenized by FAS-
T(EST)MAP shimming (Gruetter and Tkacˇ, 2000), localized
1H MRS was performed by using STEAM with an echo time
of 2.8 msec and a repetition time of 4 sec (Mlynarik et al.,
2006); 13C MRS was performed with semiadiabatic distortion-
less enhancement by polarization transfer (DEPT) combined
with 3D-ISIS 1H localization (Henry et al., 2003a); and LCMo-
del (Stephen Provencher, Oakville, Ontario, Canada) was
employed for analysis of both 1H (Mlynarik et al., 2006) and
13C (Henry et al., 2003b) spectra.
The scaling of 13C concentrations measured in vivo was
based on the FE determined in vitro in 13C MRS from perchloric
acid extracts of the brain prepared at the end of each experiment,
as described elsewhere (Duarte and Gruetter, 2013). For that,
lyophilized extracts were redissolved in 2H2O and the p
2H was
adjusted to 7.0 with 2HCl or NaO2H solutions. High-resolution
in vitro MRS was performed as detailed by Duarte et al. (2007)
with a 14.1-T DRX-600 spectrometer equipped with a 5-mm
cryoprobe (Bruker BioSpin SA, F€allenden, Switzerland).
Metabolic Modeling
Labeling incorporation from [3-13C]lactate into aliphatic
carbons glutamate and glutamine was analyzed by using the
one- and two-compartment models previously described by
Henry et al. (2002) and Duarte et al. (2011), respectively
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(Fig. 1). The mathematical models were adjusted to the 13C
enrichment curves of glutamate and glutamine by nonlinear
regression with the Levenberg-Marquardt algorithm, coupled
to a Runge-Kutta method to obtain numerical solutions of the
ordinary differential equations that define each model. The
one-compartment model was fit only to curves of glutamate
C3 and C4. In the analysis with the two-compartment model,
accuracy was improved by constraining glial metabolic fluxes
according to a previous study under identical experimental con-
ditions in which rats were infused with [1,6-13C]glucose
(Duarte et al., 2011). The flux of the glial tricarboxylic acid
(TCA; VTCA
g) cycle was constrained to 38% of the whole
mitochondrial oxidation, i.e., total pyruvate oxidation
CMRpyr(ox); the flux through pyruvate carboxylation (VPC) was
defined as 25% of VTCA
g; and the transmitochondrial 2-oxoglu-
tarate/glutamate exchange flux in the glia (VX
g) was considered
equal to Vg, which denotes the fraction of flux through glial
pyruvate dehydrogenase corresponding to the complete oxida-
tion of pyruvate. In addition to metabolic fluxes, fitted parame-
ters included the FE of glial acetyl-CoA and pyruvate in both
compartments. The reliability of measured parameters was eval-
uated by Monte-Carlo analysis (Duarte et al., 2011). The var-
iance of each parameter was estimated by fitting a gamma
function to the probability distribution resulting from 500
Monte-Carlo simulations. All numerical procedures were per-
formed in Matlab (The MathWorks, Natick, MA). Fitted
parameters are reported with SD. Remaining results are mean-
6 SEM of n5 5.
RESULTS
Blood Physiology and Substrate Enrichment
To measure blood pH and gases, plasma concentra-
tions and 13C FEs of lactate, alanine, acetate, and glucose,
arterial blood samples were collected periodically. Admin-
istration of lactate was accompanied by an increase of pH
and bicarbonate in the arterial blood without significant
effects in other measured physiological parameters (Fig.
2A). Blood pH increased from 7.356 0.01 before infu-
sion to 7.576 0.01 after 3 hr (3.0%6 0.2%), and bicar-
bonate increased from 21.16 1.2 mM to 35.46 2.5 mM
(68%6 7%) at the end of the experiment. The target
plasma lactate concentration was attained after administra-
tion of the [3-13C]lactate bolus, whereas the plasma levels
of other potential brain substrates did not vary substan-
tially (Fig. 2B). The current infusion protocol resulted in
marked hyperlactemia and fairly constant plasma lactate
C3 enrichment (0.316 0.01) 5 min after starting the
Fig. 1. Schematics of the metabolic models employed for analysis of 13C
enrichment curves measured in vivo by MRS. In the models of brain
energy metabolism with one (A) and two (B) compartments, pyruvate
(Pyr) pools are in fast equilibrium with lactate and are diluted by unla-
beled substrates, namely, glucose. VPDH
n is the neuronal TCA cycle;
Vg1VPC is the total glial TCA cycle; VPC is the rate of pyruvate carbox-
ylase. In the glial compartment, the acetyl-CoA (AcCoA) pool originates
from pyruvate and can be diluted further by glia-specific substrates. TCA
cycle intermediates oxaloacetate (OAA) and 2-oxoglutarate (OG) are in
exchange with amino acids through VX. The apparent glutamatergic
neurotransmission (i.e., glutamate–glutamine cycle) is VNT, and the glu-
tamine synthetase rate is VGS (equal to VPC1VNT). Efflux of labeling
from the metabolic system occurs through the rate of glial glutamine loss
Vefflux (equal to VPC). The superscripts g and n distinguish metabolic
pools or fluxes in the glial or neuronal compartment, respectively.
Fig. 2. Blood physiology parameters (A) and FE and concentration of
substrates in the plasma (B). In A, asterisks indicate that pH and con-
centration of HCO3– were significantly increased compared with
baseline (P< 0.05, paired t-test). In B, concentration of glucose and
lactate (Lac) were measured biochemically, whereas alanine (Ala) and
acetate (Ac) contents as well as FE were determined in plasma samples
by 1H MRS.
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administration of [3-13C]lactate. Labeling was also
observed in plasma alanine C3 and acetate C2 but not
glucose C1. Whereas FE of alanine reached a plateau at
0.216 0.02, that of acetate increased continuously
throughout the experiment (0.156 0.03 at the end).
Brain 13C-Enriched Metabolites
Initial total brain lactate content measured by 1H
MRS prior to infusion was 0.776 0.10 mmol/g. The sin-
glet resonance of lactate C3 was observed upon
[3-13C]lactate infusion (Fig. 3A) and allowed estimating
its concentration over time (Fig. 3B). In brain extracts
performed at the end of the MRS experiments, FE of lac-
tate C3 was 0.136 0.02, which was not significantly dif-
ferent from that of alanine C3 (0.106 0.01, P> 0.05,
paired t-test). Labeling of brain glucose and acetate was
undetectable both in vivo and in brain extracts. Brain lac-
tate C3 concentration measured in vivo and its enrich-
ment measured in tissue extracts were used to estimate
total brain lactate content, which was similar to that meas-
ured before [3-13C]lactate infusion (Fig. 3C).
Labeling from [3-13C]lactate into aliphatic carbons
of brain glutamate and glutamine was measured in the rat
brain with a time resolution of 18 min (Fig. 3A). Other
neurochemicals, such as g-aminobutyric acid (GABA)
and aspartate, became enriched but were not reliably
quantified at this temporal resolution (not shown). The
13C enrichment of glutamate and glutamine was quanti-
fied in brain extracts (Table I) and then used to scale the
experimental curves obtained in vivo for metabolic mod-
eling (Fig. 4). The concentration of amino acids was
assumed to remain unaltered through the whole period of
lactate infusion.
Estimation of Metabolic Fluxes
To determine the metabolic fluxes, the one- and
two-compartment models depicted in Figure 1 (for details
see Henry et al., 2002; Duarte et al., 2011) were fitted to
the average enrichment in aliphatic carbons of glutamate
and glutamine (Fig. 4A). The estimated metabolic fluxes
were similar to those previously determined upon infu-
sion of [1,6-13C]glucose (Fig. 4B). Namely, the neuronal
TCA cycle (VPDH
n) was 0.406 0.02 mmol/g/min, the
mitochondrial exchange (VX
n) was 0.686 0.33 mmol/g/
min, and the glutamate–glutamine cycle (VNT) was
0.146 0.05 mmol/g/min. Fluxes in the glial compartment
were constrained based on the relative rates measured
upon administration of [1,6-13C]glucose (Duarte et al.,
2011) as detailed in Materials and Methods. This resulted
in VPC5 0.0726 0.004 mmol/g/min and Vg5VX
g5
0.226 0.01 mmol/g/min. FE of neuronal pyruvate C3
was 0.136 0.01. In the glial compartment, FE was
0.0626 0.013 for pyruvate C3 and 0.0496 0.013 for
acetyl-CoA C2. Constraining the enrichment of these
two precursors in the glial compartment to be equal
resulted in identical fit quality and flux values (not
shown). Based on the plasma FE of 0.31 (Fig. 2B), one
can estimate that plasma lactate contributed to 43% of
neuronal pyruvate and to 20% and 17% of glial pyruvate
and acetyl-CoA, respectively.
To estimate the variability of measured fluxes across
experiments, the two-compartment model was also fitted
to 13C enrichment curves from each animal. The fit of
individual data sets resulted in mean metabolic fluxes similar
to those determined from the average curves but associated
with larger standard deviations representing both
Fig. 3. A: Typical 13C NMR spectra acquired in vivo at 14.1 T from
the rat brain during infusion of [3-13C]lactate. Each spectrum was
acquired for 18 min, and Lorentzian-Gaussian apodization was
employed with lb5 7, gf5 0.12, and gfs5 0.02. B: Brain lactate C3
content increased upon infusion of [3-13C]lactate, but its quantifica-
tion was associated with relatively high uncertainty. C: Initial concen-
tration of lactate was quantified by 1H MRS in vivo before the 13C
MRS experiment, and brain lactate content at the end was estimated
from the last data point of the labeling curve and the FE measure in
brain extracts. Data are shown as mean6 SEM for five rats.
TABLE I. FE of Glutamate and Glutamine Measured in
Perchloric Acid Extracts of the Brains From the Experiments In
Vivo
Glutamate Glutamine
C4 0.1156 0.009 0.0786 0.014
C3 0.1016 0.014 0.0726 0.022
C2 0.1086 0.016 0.0686 0.014
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experimental and biological variability. In particular, the
freely fitted fluxes VPDH
n, VX
n, and VNT were 0.336 0.14,
236 51, and 0.246 0.26 mmol/g/min, respectively. The
constrained glial fluxes VPC and Vg (5 VX
g) were
0.0596 0.026 and 0.186 0.08 mmol/g/min, respectively.
Given the number of constraints imposed on the
model, we tested the result of fitting the simple one-
compartment model to the curves of glutamate C3 and
C4 further. The fit of the one-compartment model
resulted in VPDH and VX of 0.336 0.02 and 3.06 116.0
mmol/g/min, respectively. The dilution of glutamate by
unlabeled glutamine (Vgln) was 0.0336 0.009 mmol/g/
min, and the FE of pyruvate C3 was 0.126 0.01. These
parameters were indistinct from those measured with the
two-compartment model (Fig. 4B) and remained unal-
tered (VPDH5 0.336 0.01 mmol/g/min, Vgln5
0.0316 0.008 mmol/g/min) when VX was fixed to 5
mmol/g/min, a value that is one order of magnitude
higher than the TCA cycle rates determined with the
two-compartment model (Henry et al., 2002).
Effect of Model Assumptions on Flux Estimation
In the current study, the fluxes in the glial compart-
ment could not be accurately estimated without imposing
constraints on the mathematical model. It was assumed
that VPC was 25% of VTCA
g. Smaller VPC values had little
effect on the estimated parameters, but a relative increase
affected mostly VNT and VX
n (Fig. 5A). For example, the
increase of VPC/VTCA
g by 20% resulted in an increase of
VPC (24%) and VNT (40%) and a reduction of VX
n (28%).
It should be noted that lower VPC relative to VTCA
g led
to poorer estimation of VX
n. The lowest sum of squared
residuals (SSR) was obtained with VPC at 20% of VTCA
g.
VTCA
g was constrained to 38% of the total pyruvate
oxidation, CMRpyr(ox). A modification in the ratio of VTCA
g
to CMRpyr(ox) resulted in prominent alterations not only in
glial but also in neuronal fluxes (Fig. 5B). The relative
increase in VTCA
g was, as expected, associated with dimin-
ished neuronal oxidative metabolism, depicted by VPDH
n.
VNT was modified principally when the fraction of glial oxi-
dative metabolism was increased. For example, when consid-
ering that VTCA
g was 46% of CMRpyr(ox), VNT was
0.196 0.06 mmol/g/min; i.e., it was overestimated by 37%.
Both increase and decrease of the fraction of VTCA
g led to an
increase of SSR, i.e., reduction of fit quality.
The assumption in the value of the glial transmito-
chondrial exchange flux VX
g was virtually devoid of effects
in the parameters estimated by the mathematical model
(Fig. 5C). Similarly, varying the relative concentrations of
glutamate and glutamine and their distribution within the
glial and neuronal compartments did not cause major altera-
tions to the estimated fluxes (Fig. 6). An increase in the rel-
ative size of the glial pool of glutamate was, however,
associated with poorer fitting, i.e., a large increase in SSR.
DISCUSSION
The current article describes the metabolic fluxes of brain
energy metabolism in the rat brain in vivo, measured
with 13C-enriched lactate as tracer. Although lactate is
transported across the blood–brain barrier with a perme-
ability about half of that of glucose (Knudsen et al., 1991),
this study shows that, upon administration of [3-13C]lac-
tate, 13C MRS can be used to study energy metabolism in
the rodent brain under normoglycemic conditions. Meta-
bolic fluxes determined with [3-13C]lactate were similar
to those estimated with other tracers, namely, isotopes of
glucose under identical experimental conditions (for
review see Lanz et al., 2013).
Lactate Transport and Utilization
Although lactate C3 peaks were identifiable by 13C
MRS in vivo, the quantification was not sufficiently reli-
able to estimate lactate uptake from blood. Nevertheless,
lactate concentration was 0.77 mmol/g in the rat brain
Fig. 4. FE in carbons of glutamate (Glu) and glutamine (Gln) meas-
ured in vivo by 13C MRS (A) and resulting metabolic fluxes (B). In
A, curves of the best fit of the one- and two-compartment models are
represented by dashed and solid lines, respectively. Data are shown as
mean6 SEM for five rats. B shows the metabolic fluxes obtained by
fitting the two-compartment model to 13C enrichment curves of glu-
tamate and glutamine from experiments with administration of
[3-13C]lactate (open bars) or [1,6-13C]glucose (haycheded bars; data
from Duarte et al., 2011). Error bars of fluxes are SD.
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under a-chloralose before [3-13C]lactate infusion and was
not augmented markedly upon infusion. At the end of
the experiment, brain lactate enrichment was only 13% in
C3.
The mechanism by which lactate crosses the human
blood–brain barrier is equilibrative (Knudsen et al., 1991).
Lactate influx into the rat brain consists of a saturable,
stereospecific component to the L-enantiomer with trans-
port rate constants that are approximately 50% of those
for glucose and a nonsaturable, nonstereospecific diffusion
component that has been determined from D-lactate
influx (Lear and Kasliwal, 1991; LaManna et al., 1993). A
13C MRS study in humans confirmed that, indeed, brain
lactate uptake and metabolism increase with plasma lactate
concentration (Boumezbeur et al., 2010). From this study,
it can be estimated that the maximum contribution of
plasma lactate to the whole-brain oxidative metabolism is
2–3% at physiological plasma lactate levels (1–1.5 mM)
and can reach 60% at supraphysiological plasma lactate
levels, i.e., when carriers are nearly saturated. Further-
more, 13C enrichment patterns in glutamate and gluta-
mine indicate that lactate metabolism in the brain is
similar to that of glucose (Boumezbeur et al., 2010). This
was reproduced in the current study, in which blood lac-
tate at supraphysiological levels contributed to 43% of
neuronal pyruvate in the rat brain. In contrast, glial pyru-
vate received a contribution of plasma lactate of only
20%. However, the exact value of lactate utilization was
not directly estimated in the current study. The cerebral
metabolic rate of lactate (CMRlac) increases with increas-
ing lactemia (Gallagher et al., 2009; Boumezbeur et al.,
2010; Rasmussen et al., 2010; van Hall, 2010). Lactate
transport was evaluated in several regions of the rat brain
by LaManna et al. (1993). By using the mean kinetic
parameters described in this study, excluding those for
cerebellum, transport into and out of the brain was 0.27
and 0.07 mmol/g/min at our lactate concentrations. At
steady state, CMRlac is thus 0.20 mmol/g/min. By sub-
tracting CMRlac from the whole pyruvate oxidation, glu-
cose utilization (CMRglc) was 28 mmol/g/min. Although
this rate of glucose oxidation is much smaller than what
had been determined under the same experimental condi-
tions but normolactemia (Duarte et al., 2011; Duarte and
Gruetter, 2012, 2013), it is well known that increases in
Fig. 5. Effect of the constraints imposed to VPC (A), VTCA
g (B), and VX
g (C) on parameter estima-
tion with the two-compartment model. Vertical dashed lines represent the assumptions used for
parameter estimation. Error bars are SD. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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lactate uptake and oxidation are paralleled by glycolysis
inhibition (Hertz et al., 2014).
Transport of lactate is pH dependent (Oldendorf
et al., 1979; Knudsen et al., 1991), and hyperlactemia
raises blood pH, as observed by others (Leegsma-Vogt
et al., 2003; Smith et al., 2003). Nevertheless, variable
contribution of lactate consumption was not considered
for the modeling of brain energy metabolism. Although
lactate transport kinetics were not measured in the current
study, at supraphysiological levels of plasma lactate the
variation of pH in 0.2 units is unlikely to affect its cerebral
metabolic rate. From the data published by Oldendorf
et al. (1979) on Wistar rats under pentobarbital anesthesia
and normolactemia, the increase in pH observed in the
current study would result in a reduction of lactate uptake
by only 8%, which is within the standard deviation of
measured lactate uptake.
Energy Metabolism in Neurons and Glia
Infusion of unlabeled glucose prevented labeling
from appearing in the positions C1 and C6 as a result of
[3-13C]lactate recycling through liver gluconeogenesis
(Sampol et al., 2013; see also Bouzier et al., 2000; Bou-
mezbeur et al., 2010). Indeed, glucose labeling was unde-
tectable either in vivo or in brain extracts, ensuring that
the 13C enrichment observed in amino acids was derived
mainly from [3-13C]lactate. The current mathematical
models did not include 13C incorporation from alanine or
acetate that became enriched in plasma. Given the low
concentration of alanine relative to lactate in the blood
(6- to 13-fold lower; Fig. 2B) and its relatively low trans-
port rate, blood-borne 13C-enriched alanine is unlikely to
contribute significantly to brain metabolism (Duarte et al.,
2011). Thus, the amount of [3-13C]alanine measured in
the brain probably resulted from brain metabolism of
Fig. 6. Relative size of glutamate and glutamine pools has little effect on the estimated parameters
with the two-compartment model. A: Effect of total glutamine concentration while glutamate
remained unvaried. B,C: Effect of the relative distribution of glutamate and glutamine in each com-
partment, respectively. Vertical dashed lines represent the assumptions used for parameter estimation.
Error bars are SD. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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[3-13C]lactate. Plasma acetate content was also four- to
sevenfold lower than lactate content, and, moreover,
[2-13C]acetate was undetectable in the brain. Neverthe-
less, the model allowed for different FE in pyruvate and
acetyl-CoA, representing glial acetate utilization. In glia,
the estimated FE was similar for acetyl-CoA and pyruvate
(in the two-compartment model), suggesting minor utili-
zation of acetate that would dilute the pool of acetyl-CoA
relative to that of pyruvate.
In the current experiments, plasma lactate at supra-
physiological levels (5 mM) contributed to 43% and
20% of neuronal and glial oxidative metabolism, respec-
tively. Blood-born [3-13C]lactate was thus more diluted
in astrocytes than in neurons, leading to pyruvate enrich-
ment of 6% and 13%, respectively, which suggests prefer-
ential utilization of unlabeled substrates, such as glucose
and glycogen, within the glial compartment. Indeed, glial
glycogen is essential for the maintenance of the homeosta-
sis of extracellular depolarizing agents such as glutamate
and potassium (Sickmann et al., 2009; Xu et al., 2013)
and constitutes an important precursor for the de novo
synthesis of glutamate and glutamine (Gibbs et al., 2007).
Given the role of astrocytes in substrate uptake from the
blood stream and delivery to neurons, the current data are
consistent with the presence of at least two distinct lactate
pools in astrocytes, one being used to support neurons
and not prone to glial oxidation. Astrocytes have been
suggested to consume, eventually, as much lactate as neu-
rons or even more (Zielke et al., 2007; Gandhi et al.,
2009). In this case, the current results indicate that this
lactate is not of peripheral origin but probably is locally
produced. Moreover, it has been proposed that the rat
brain comprises one pool of lactate that exchanges with
plasma lactate “that can be filled and emptied in accord-
ance to blood lactate concentration” and that is not used
as an energy supply (Leegsma-Vogt et al., 2003). This is
also compatible with subcellular compartmentation of
glucose and lactate metabolism; i.e., lactate production
and oxidation of exogenous lactate are functionally sepa-
rate metabolic pathways. This has been proposed to occur
in astrocytes (Brand et al., 1992) and neurons (Cruz et al.,
2001) or in peripheral organs, such as the heart (Chatham
et al., 2001).
Because of the small enrichment of amino acids,
particularly glutamine that was at most 8%, corresponding
to nearly 0.4 mmol/g in comparison to the experiment
with 13C-enriched glucose administration (Duarte et al.,
2011; Duarte and Gruetter, 2013), a possible difference in
C2 and C3 enrichment curves was not clearly identified.
Thus, the flux through pyruvate carboxylase could not be
determined accurately in vivo. Therefore, the FE was
determined in the brain extracts at the end of the experi-
ment in vivo for glutamine C2 and C3 and found to be
similar (Table I), which further suggests that lactate is
metabolized mainly in the neuronal compartment
deprived of pyruvate carboxylase activity (Bouzier et al.,
2000; Sampol et al., 2013).
In the current experiments, the use of [3-13C]lactate
did not allow accurate determination of metabolic fluxes
in glia. Given the relatively small FE observed in brain
amino acids, mathematical constraints were imposed on
the model. Namely, VTCA
g, VPC, and VX
g were fixed rel-
ative to the whole oxidation rate of the brain and among
each other. The relative values of these fluxes were based
on the findings in experiments with [1,6-13C]glucose that
produces high FE in brain metabolites and thus leads to
high sensitivity in MRS. Nevertheless, variation of these
constraints within reasonable limits had minor effects on
modeling results.
The data were further analyzed with a one-
compartment model fitted only to the experimental
curves of glutamate C3 and C4, which are least affected
by experimental noise (see Fig. 3). Although it does not
provide any information on the metabolic compartmenta-
tion, this analysis does not require flux constraining,
which may be advantageous for flux estimation. Because
glutamate resides mostly in neurons, one can assume that
the estimated VPDH is a close representation of VPDH
n.
Whereas the two models rendered similar precision in the
estimation of VPDH (SD 5–6%) and FE of Pyr3 (SD 8%)
in neurons, the fitting with the two-compartment model
resulted in larger VPDH. From the FE of Pyr3 in the one-
compartment model, one can estimate that brain pyruvate
received a contribution of 39% from plasma lactate, which
is not substantially different from the contribution to
Pyr3
n of 43% determined by using two compartments.
The signal-to-noise ratio achieved in the current
experiments was much lower than that in experiments
under identical conditions but with infusion of 13C-
enriched glucose (Duarte et al., 2011; Duarte and Gruet-
ter, 2013) because the observed metabolites were fivefold
less enriched. This limited the analysis to the most con-
centrated amino acids, glutamate and glutamine, and
restricted the temporal resolution to 18 min. Only gluta-
mate C4 could be reliably quantified at a higher temporal
resolution. Metabolic modeling including glutamate C4
with a resolution of 10 min did not affect the estimation
of metabolic fluxes substantially (not shown).
Although rates of oxidative metabolism were similar
to those measured with 13C-glucose, the utilization of
lactate might be associated with a reduction in glucose
metabolic rate (Smith et al., 2003). Nevertheless, the
results from this study do not exclude that hyperlactemia
might affect metabolic interactions between the cellular
compartments. We conclude that extracerebral lactate can
be used as fuel by the brain under normoglycemic condi-
tions, leading mostly to production of pyruvate for neuro-
nal oxidation.
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